Neumora Therapeutics (NASDAQ:NMRA - Get Free Report)'s stock had its "outperform" rating reissued by analysts at William Blair in a research report issued on Wednesday,RTT News reports.
A number of other equities analysts have also recently weighed in on NMRA. HC Wainwright reaffirmed a "buy" rating and issued a $30.00 price objective on shares of Neumora Therapeutics in a research note on Friday, January 3rd. Royal Bank of Canada cut Neumora Therapeutics from an "outperform" rating to a "sector perform" rating and dropped their price target for the company from $29.00 to $4.00 in a research report on Thursday, January 2nd. Needham & Company LLC reiterated a "buy" rating and issued a $23.00 price objective on shares of Neumora Therapeutics in a research report on Thursday, January 2nd. JPMorgan Chase & Co. downgraded shares of Neumora Therapeutics from an "overweight" rating to a "neutral" rating and dropped their target price for the company from $18.00 to $15.00 in a report on Tuesday, November 5th. Finally, Bank of America cut their target price on shares of Neumora Therapeutics from $22.00 to $7.00 and set a "buy" rating for the company in a research report on Monday, January 6th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $16.50.
Check Out Our Latest Report on NMRA
Neumora Therapeutics Trading Down 3.5 %
Shares of NASDAQ NMRA traded down $0.08 during midday trading on Wednesday, reaching $2.20. 2,768,851 shares of the company were exchanged, compared to its average volume of 12,194,753. Neumora Therapeutics has a 1 year low of $1.83 and a 1 year high of $21.00. The stock has a fifty day simple moving average of $9.16 and a 200 day simple moving average of $11.17. The stock has a market cap of $355.43 million, a P/E ratio of -1.18 and a beta of 2.71.
Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.06). During the same period last year, the business posted ($1.14) EPS. As a group, analysts forecast that Neumora Therapeutics will post -1.61 earnings per share for the current year.
Insider Activity at Neumora Therapeutics
In other news, Director Matthew K. Fust sold 14,049 shares of the business's stock in a transaction on Friday, October 18th. The shares were sold at an average price of $17.03, for a total transaction of $239,254.47. Following the completion of the sale, the director now directly owns 20,100 shares of the company's stock, valued at $342,303. The trade was a 41.14 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 26.40% of the company's stock.
Institutional Trading of Neumora Therapeutics
Institutional investors have recently modified their holdings of the company. Amalgamated Bank raised its position in Neumora Therapeutics by 472.8% in the second quarter. Amalgamated Bank now owns 2,910 shares of the company's stock valued at $29,000 after purchasing an additional 2,402 shares during the period. Quarry LP acquired a new stake in shares of Neumora Therapeutics in the second quarter valued at about $98,000. SkyOak Wealth LLC purchased a new stake in shares of Neumora Therapeutics during the 2nd quarter valued at about $147,000. Intech Investment Management LLC acquired a new position in Neumora Therapeutics during the 3rd quarter worth approximately $175,000. Finally, Ballentine Partners LLC purchased a new position in Neumora Therapeutics in the 3rd quarter worth approximately $178,000. Hedge funds and other institutional investors own 47.65% of the company's stock.
About Neumora Therapeutics
(
Get Free Report)
Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.
Featured Articles
Before you consider Neumora Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neumora Therapeutics wasn't on the list.
While Neumora Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
